Aspirin reduces risk of death in hospitalized Covid-19 patients: Study – more way of life


A new study led by researchers at the University of Maryland School of Medicine (UMSOM), has found that hospitalised Covid-19 patients who were taking a day by day low-dose aspirin to give protection to against cardiovascular disease had a significantly lower risk of complications and death compared to people who did not take aspirin.

Aspirin takers were less likely to be placed in the intensive care unit (ICU) or hooked up to a mechanical ventilator, and they were much more likely to continue to exist the infection in comparison to hospitalised patients who were not taking aspirin.

The study, published in the publication Anesthesia and Analgesia, provides “cautious optimism,” the researchers say, for a cheap, accessible medication with a well-known safety profile that could help prevent severe complications.

“This can be a critical finding that must be confirmed through a randomized clinical trial. Whether our finding is confirmed, it would make aspirin the first widely to be had, over the counter medication to minimize mortality in COVID-19 patients,” said study leader Jonathan Chow, MD, Assistant Professor of Anesthesiology at UMSOM.

To conduct the study, Dr Chow and his colleagues culled through the medical records of 412 COVID-19 patients, age of 55 on average, who were hospitalized during the last few months because of complications of their infection.

They were treated at the University of Maryland Medical Center in Baltimore and three other hospitals along the East Coast. Approximately a quarter of the patients were taking a day by day low-dose aspirin (generally 81 milligrams) before they were admitted or correct after admission to administer their cardiovascular disease.

The researchers found aspirin use used to be associated with a 44 per cent discount in the risk of being put on a mechanical ventilator, a 43 per cent decrease in the risk of ICU admission, and — most importantly — a 47 per cent decrease in the risk of dying in the hospital compared to people who were not taking aspirin. The patients in the aspirin group did not experience a remarkable increase in adverse events such as major bleeding while hospitalised.

The researchers controlled for several factors that may have played a role in a patient’s prognosis including age, gender, body mass index, race, high blood pressure, and diabetes. They also accounted for heart disease, kidney disease, liver disease, and using beta blockers to regulate blood pressure.

COVID-19 infections increase the risk of dangerous blood clots that can form in the heart, lungs, blood vessels, and other organs. Complications from blood clots can, in infrequent cases, cause heart attacks, strokes, and more than one organ failure in addition to death.

Doctors ceaselessly recommend day by day low-dose aspirin for patients who have up to now had a heart attack or stroke caused by a blood clot to prevent future blood clots. Day-to-day use, alternatively, can increase the risk of major bleeding or peptic ulcer disease.

“We imagine that the blood thinning effects of aspirin provides benefits for COVID-19 patients by preventing microclot formation,” said study co-author Michael A. Mazzeffi, MD, Associate Professor of Anesthesiology at UMSOM.

“Patients diagnosed with COVID-19 may need to imagine taking a day by day aspirin so long as they check with their doctor first,” added Mazzeffi.

Those at increased bleeding risk because of chronic kidney disease, for instance, or because they incessantly use sure medications, like steroids or blood thinners, would possibly not have the ability to safely take aspirin, he added.

Researchers from Wake Forest School of Medicine, George Washington University School of Medicine, Northeast Georgia Health System, and Walter Reed National Military Medical Center also participated in this study.

“This study adds to the tremendous work our researchers are doing in the School of Medicine to help find new treatments against COVID-19 and save patients’ lives,” said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Matters, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean, University of Maryland School of Medicine.

“While confirmatory studies are needed to prove that aspirin use results in better outcomes in COVID-19, the evidence thus far suggests that patients may need to discuss with their doctor if it is secure for them to take aspirin to administer potentially prevent serious complications,” added Reece.

(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)

Follow more stories on Facebook and Twitter

Top stories / News


Please enter your comment!
Please enter your name here